For all its brutal cost in human suffering, the unfolding zika epidemic has provided a rich source of learning materials for the nation’s blood supply. In one sense, it is profoundly reassuring to the speed with which US regulatory agencies, pharmaceutical companies, and individual members of the blood supplier community have worked together to address an unfolding crisis.